The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Imviva Biotech's CTD402 to accelerate the ...
Potential treatment for patients with breast cancer with metastasis to the brain with crofelemer would augment the significant responder analysis results for crofelemer in the prespecified subgroup of ...
Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that the U.S. Food and Drug Administration has granted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results